Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754692 | 0.96 | SIGMAR1 (0.38) | SIGMAR1SLC6A4HRH3SLC6A2HRH1 | |
| SCHEMBL25754686 | 0.95 | HRH3 (0.39) | SIGMAR1SLC6A4HRH3SLC6A2HRH1 | |
| SCHEMBL25754682 | 0.90 | SLC6A3 (0.39) | SIGMAR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL25754695 | 0.90 | HRH3 (0.40) | SIGMAR1SLC6A4HRH3SLC6A2HRH1 | |
| SCHEMBL25754663 | 0.90 | HRH3 (0.40) | SIGMAR1SLC6A4HRH3SLC6A2HRH1 | |
| SCHEMBL25754672 | 0.88 | HRH3 (0.37) | SIGMAR1SLC6A4HRH3SLC6A2HRH1 | |
| SCHEMBL25754676 | 0.88 | HRH3 (0.40) | SIGMAR1SLC6A4HRH3SLC6A2HRH1 | |
| SCHEMBL25754568 | 0.85 | HRH3 (0.43) | SIGMAR1SLC6A4HRH3SLC6A2HRH1 | |
| SCHEMBL25754668 | 0.85 | SLC6A3 (0.39) | SIGMAR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL25754580 | 0.83 | HRH3 (0.48) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | SIGMAR1 4773/4885SLC6A4 4774/4885HRH3 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.